Pharmacological aspects of cognitive impairment: Past, present and future of drugs in dementia

Journal of Applied Biomedicine

Volumn 5, Issue 2, 2007, Pages 57-70

  Isensee, Kathleen ^a   Petroianu, Georg ^b   Stark, Holger ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

Animal models; Cholin esterase inhibitors; H3 receptor; Histamine H3; Histaminergic neurotransmission; NMDA; Receptor antagonist; Therapy; amyloid peptide; protein

Indexed keywords

2 AMINO 1 [4 [3 (4 CYCLOPROPANECARBONYLPHENOXY)PROPYL] 1 PIPERAZINYL] 1 PROPANONE; 5 (4 CYANOPHENYL) 2 [2 (2 METHYL 1 IMIDAZOLIDINYL)ETHYL]BENZOFURAN; ACETYLCHOLINE; AMPHETAMINE; AMYLOID BETA PROTEIN; BF 2649; CIPROXIFAN; DESIPRAMINE; DONEPEZIL; GALANTAMINE; GSK 189254; GT 2331; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR ANTAGONIST; JNJ 5207852; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NITROMEMANTINE DERIVATIVE; NOOTROPIC AGENT; RIVASTIGMINE; SEROTONIN 4 AGONIST; SEROTONIN 4 RECEPTOR; TACRINE; THIOPERAMIDE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMNESIA; ATTENTION DEFICIT DISORDER; CATAPLEXY; COGNITIVE DEFECT; DEMENTIA; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; HUMAN; LIVER FUNCTION TEST; MEMORY DISORDER; NAUSEA; NEUROTRANSMISSION; NONHUMAN; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; VOMITING; WAKEFULNESS;

ANIMALIA;

EID: 34250682954     PISSN: 1214021X     EISSN: 12140287     Source Type: Journal    
DOI: 10.32725/jab.2007.008     Document Type: Review

References (97)

1. 3 receptor antagonists with combined inhibitory potency at N-methyltransferase: Ether derivatives. Pharmazie 60:79-106, 2005.
2. 3-receptors. Nature 327:117-123, 1987.
3. Bacciottini L, Mannaioni PF, Chiappetta M, Giovannini MG, Blandina P: Acetylcholine release from hippocampus of freely moving rats is modulated by thioperamide and cimetidine. Inflamm. Res. 48:63-64, 1999.
4. Bacciottini L, Giovannelli L, Passani MB, Schunack W, Mannaioni PF, Blandina P: Endogenous histamine in the medial septum-diagonal band complex increases the release of acetylcholine from the hippocampus: A dual-probe microdialysis study in the freely moving rat. Eur. J. Neurosci. 15:1669-1680, 2002.
5. Bamford MJ, Dean DK, Sehmi SS, Wilson DM, Witherington J: Benzodiazepine derivatives for the treatment of neurological disorders. WO 2004/056369, 2004.
6. 3 antagonist. Br. J. Pharmacol. 143:649-661, 2004.
7. Bekkers JM: Enhancement by histamine of NMDA-mediated synaptic transmission in the hippocampus. Science 261:104-106, 1993.
8. 3 receptor activation in rats. Br. J. Pharmacol. 119:1656-1564, 1996.
9. Block W: Galantamine: Revives memory and helps fight Alzheimer's. www.galantamine.cc/articles/galantamine-articles-5.htm (accessed on April 19, 2007).
10. 3 receptor antagonists: From target indentification to drug leads. Biochem. Pharmacol. 73:1084-1096, 2007.
11. Brown RE, Stevens DR, Haas HL: The physiology of brain histamine. Prog. Neurobiol. 63:637-672, 2001.
12. Bullock R: Future directions in the treatment of Alzheimer's disease. Expert Opin. Investig. Drugs 13:303-314, 2004.
13. Burns A, O'Brien J: Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J. Psychopharmacol. 20:732-755, 2006.
14. Cecchi M, Giorgetti M, Bacciottini L, Giovannini MG, Blandina P: Increase of acetylcholine release from cortex of freely moving rats by administration of histamine into the nucleus basalis magnocellularis. Inflamm. Res. 47:32-33, 1998.
15. 3 receptor agonist and antagonist on histamine co-transmitter expression in rat brain. J. Neural Transm. 109:293-306, 2002.
16. 4 receptor gene. Biochem. Biophys. Res. Commun. 284:301-309, 2001.
17. 3 antagonists. Inflamm. Res. 53:69-70, 2004a.
18. 3 antagonists: 2-aminoethylbenzofurans. Bioorg. Med. Chem. Lett. 14:689-693, 2004b.
19. Cumming P, Vincent SR: Inhibition of histamine-N-methyltransferase (HNMT) by fragments of 9-amino-1,2,3,4-tetrahydroacridine (Tacrine) and by β-carbolines. Biochem. Pharmacol. 44: 989-992, 1992.
20. Cummings JL: Cholinesterase inhibitors; a new class of psychotropic compounds. Am. J. Psychiatry 157:4-15, 2000.
21. Decker JLM, McGaugh JL: The role of interactions between the cholinergic system and other neuromodulatory systems in learing and memory. Synapse 7:151-168, 1991.
22. Delagarza VW: Pharmacologic treatment of Alzheimer's disease: An update. Am. Fam. Physician 68:1365-1372, 2003.
23. 3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effects. J. Pharmacol. Exp. Ther. 305:887-896, 2003.
24. 3 receptor antagonist. Biochem. Pharmacol. 68:933-945, 2004.
25. Everitt BJ, Robbins TW: Central cholinergic systems and cognition. Annu. Rev. Psychol. 48:649-684, 1997.
26. 3 receptor antagonist, ondansetron. Psychopharmacology (Berl.) 118:82-92, 1995.
27. 3 receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup. Behav. Brain Res. 131:151-161, 2002.
28. 3 receptor antagonists A-304121 and A-317920: II. In vivo behavioral and neurophysiological characterization. J. Pharmacol. Exp. Ther. 305:897-908, 2003.
29. 3 receptor antagonist. J. Pharmacol. Exp. Ther. 313:176-190, 2005.
30. 3-receptor antagonists. Arch. Pharm. 331:395-404: 1998.
31. +-evoked release of acetylcholine from rat cortex in vivo. Inflamm. Res. 46:33-34, 1997.
32. Giorgetti M, Bacciottini L, Giovannini MG, Colivicchi MA, Goldfarb J, Blandina P.: Local GABAergic modulation of acetylcholine release from the cortex of freely moving rats. Eur. J. Neurosci. 12:1941-1948; 2000.
33. 3 receptor agonists and antagonists on cognitive performance and scopolamine-induced amnesia. Behav. Brain Res. 104:147-155, 1999.
34. Givens B, Sarter M: Modulation of cognitive processes by transsynaptic activation of the basal forebrain. Behav. Brain Res. 84:1-22, 1997.
35. 3 receptor affinities. Bioorg. Med. Chem. 11:2163-2174, 2003.
36. Green VJ, Pirmohamed M, Kitteringham NR, Knapp MJ, Park BK: Glutathione S-transferase mu genotype (GSTM1*0) in Alzheimer's patients with Tacrine transaminitis. Br. J. Clin. Pharmacol. 39:411-415, 1995.
37. Hahn B, Shoaib M, Stolerman IP: Nicotine-induced enhancement of attention in the five-choice serial reaction time task: The influence of task demands. Psychopharmacology (Berl.) 162:129-137, 2002.
38. 3 receptor ligands, and neurological disease. Expert Opin. Investig. Drugs 13: 1237-1248, 2004.
39. 3 antagonists /inverse agonists. Biochem. Pharmacol. 71:1103-1113, 2006.
40. Holmstedt B: Structure-activity relationship of the organophosphorus anticholinesterase agents. In Koelle GB (ed): Cholinesterases and Anticholinesterase Agents, Berlin, 1963, pp. 429-485.
41. Hough LB: Genomics meets histamine receptors: New subtypes, new receptors. Mol. Pharmacol. 59:415-419, 2001.
42. 3 receptors. Eur. J. Pharmacol. 433:141-150, 2001.
43. Jann MW: Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy 20:1-12, 2000.
44. Jia JP, Jia JM, Zhou WD, Xu M, Chu CB, Yan X, Sun YX: Differential acetylcholine and choline concentrations in the cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia. Chin. Med. J. 117:1161-1164, 2004.
45. Julian PL, Pikl J: The complete synthesis of Physostigmine (Eserine). J. Am. Chem. Soc. 57:755-757, 1935.
46. Krall WJ, Sramek JJ, Cutler NR: Cholinesterase inhibitors: A therapeutic strategy for Alzheimer's disease. Ann. Pharmacother. 33: 441-450, 1999.
47. 3 receptor antagonist, thioperamide, inhibits adrenal steroidogenesis and histamine binding to adrenocortical microsomes and binds to cytochrome P450. Br. J. Pharmacol. 107:161-164, 1992.
48. Lane RM, Potkin SG, Enz A: Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int. J. Neuropsychopharmacol. 9: 101-124, 2006.
49. 3 receptor drugs. Nat. Rev. Drug Discov. 4: 107-120, 2005.
50. 3-receptor antagonist. J. Pharmacol. Exp. Ther. 287:658-666: 1998.
51. 3 receptors: Role of two amino acids in the third transmembrane domain. Br. J. Pharmacol. 131:1247-1250, 2000.
52. 3 receptor: Preclinical pharmacology. J. Pharmacol. Exp. Ther. 320:365-375, 2007.
53. Lipton SA: Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx 1:101-110, 2004.
54. 4) expressed in bone marrow. Mol. Pharmacol. 59:420-426, 2001.
55. Lleo A, Greenberg SM, Growdon JH: Current pharmacotherapy for Alzheimer disease. Annu. Rev. Med. 57:513-533, 2006.
56. 3 receptor reveals distinct species pharmacological profiles. J. Pharmacol. Exp. Ther. 293:771-778, 2000.
57. 3 receptors in Alzheimer's Disease brain and improves cognitive performance in preclinical models. J. Pharmacol. Exp. Ther. 321:1032-1045, 2007.
58. 3 antagonist, on the step-through passive avoidance response and histidine decarboxylase activity in senescence-accelerated mice. Pharmacol. Biochem. Behav. 50:321-325, 1995.
59. 3-receptor antagonists. Eur. J. Pharm. Sci. 13: 249-259, 2001.
60. Melnikova I: Therapies for Alzheimer's disease. Nat. Rev. Drug Discov. 6:341-342, 2007.
61. Mochizuki T, Okakura-Mochizuki K, Horii A, Yamamoto Y, Yarnatodani A: Histaminergic modulation of hippocampal acetylcholine release in vivo. J. Neurochem. 62:2275-2282, 1994.
62. Monti JM: Involvement of histamine in the control of the waking state. Life Sci. 53:1331-1338, 1993.
63. Morisset S, Traiffort E, Schwartz JC: Inhibition of histamine versus acetylcholine metabolism as a mechanism of Tacrine activity. Eur. J. Pharmacol. 315:R1-R2, 1996.
64. Morphy R, Kay C, Rankovic Z: From magic bullets to designed multiple ligands. Drug Discov. Today 9:641-651, 2004.
65. Muir JL, Everitt BJ, Robbins TW: AMPA-induced excitotoxic lesions of the basal forebrain: a significant role for the cortical cholinergic system in attentional function. J. Neurosci. 14: 2313-2326, 1994.
66. Munoz-Torrero D, Camps P: Dimeric and hybrid anti-Alzheimer drug candidates: Curr. Med. Chem. 13:399-422, 2006.
67. Neumann R, Peter HH: Insecticidal organophosphates: Nature made them first. Experientia 43: 1235-1237, 1987.
68. Orr EL, Quay WB: The effects of castration on histamine levels and 24-hour rhythm in the male rat hypothalamus. Endocrinology 96:941-945, 1984.
69. Ortho-Mcneil neurologics: http://www.rxforsafety.com/news/index.htm (accessed on April 19, 2007).
70. Panula P, Rinne J, Kuokkanen K, Eriksson KS, Sallmen T, Kalimo H, Relja M: Neuronal histamine deficit in Alzheimer's disease. Neuroscience 82:993-997, 1997.
71. 3 receptor modulation of cortical cholinergic function: A parallel story. Methods Find Exp. Clin. Pharmacol. 20: 725-733, 1998.
72. Passani MB, Blandina P: The neuronal histaminergic system in cognition. Curr. Med. Chem. CNS Agents. 4:17-26, 2004.
73. 3 receptor-mediated impairment of contextual fear conditioning and in-vivo inhibition of cholinergic transmission in the rat basolateral amygdala. Eur. J. Neurosci. 14:1522-1532, 2001.
74. 3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol. Sci. 25:618-625, 2004.
75. 3 receptor antagonists as potential procognitive agents. Pharmazie 61:179-182, 2005.
76. Plaitakis A, Duvoisin RC: Homer's moly identified as Galanthus nivalis L.: Physiologic antidote to Stramonium poisoning. Clin. Neuropharmacol. 6:1-5, 1983.
77. Prast H, Fischer H, Prast M, Philippu A: In vivo modulation of histamine release by autoreceptors and muscarinic acetylcholine receptors in the rat anterior hypothalamus. Naunyn Schmiedebergs Arch. Pharmacol. 350: 599-604, 1994.
78. Prast H, Fischer H, Tran ME, Grass K, Lamberti C, Philippu A: Modulation of acetylcholine release in the ventral striatum by histamine receptors. Inflamm. Res, 46:37-38, 1997.
79. Proudfoot A: The early toxicology of Physiostigmine: A tale of beans, great men and egos. Toxicol. Rev. 25:99-138, 2006.
80. Rogawski MA, Wenk GL: The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug. Rev. 9:275-308, 2003.
81. Roth BL, Sheffler DJ, Kroeze WK: Magic shotguns versus magic bullets: Selectively non-selective drugs for mood disorders and schizophrenia. Drug Discov. Today 3:353-359, 2004.
82. Selbach O, Brown RE, Haas HL: Long-term increase of hippocampal excitability by histamine and cyclic AMP. Neuropharmacology 36:1539-1548, 1997.
83. 3 receptor-mediated inhibition of serotonin release in the rat brain cortex. Naunyn Schmiedebergs Arch. Pharmacol. 337:588-590, 1988.
84. 3 receptors. J. Neural. Transm. 93:1-10, 1993.
85. 3 receptors. Naunyn Schmiedebergs Arch. Pharmacol. 340: 633-638, 1989.
86. 3 receptor-mediated inhibition of noradrenaline release in the human brain. Fundam. Clin. Pharmacol. 13:120-122, 1999.
87. 4 receptor ligands. Expert Opin. Ther. Pat. 13: 851-865, 2004a.
88. Stark H: Turning from monogamy to strategic promiscuity. Drug Discov. Today 9:736-737, 2004b.
89. Sugimoto H, Ogura H, Arai Y, Iimura Y, Yamanishi: Research and development of Donepezil hydrochloride, a new type of acetylcholinesterase inhibitor. Jpn. J. Pharmacol. 89:7-20, 2002.
90. Summers WK: Tacrine, and Alzheimer's treatments. J. Alzheimers Dis. 9:439-445, 2006.
91. 3 receptor antagonists, in two functional models. Eur. J. Pharmacol. 351: 307-311, 1998.
92. 3 antagonists. WO-03103669, 2003.
93. Tuomisto L, Tuomisto J: Diurnal variations in brain and pituitary histamine and histamine-N-methyltransferase in the rat and guinea pig. Med. Biol. 60:204-209, 1982.
94. Wada H, Inagaki N, Yamatodani A, Watanabe T: Is the histaminergic neuron system a regulatory center for whole-brain activity? Trends Neurosci. 14:415-418, 1991.
95. Wimo A, Winblad B, Aguero-Torres H, von Strauss E: The magnitude of dementia occurrence in the world. Alzheimer Dis. Assoc. Disord. 17:63-67, 2003.
96. 3 receptor antagonists with human adrenal cytochrome P450 enzymes. Pharmacology 66:128-135, 2002.
97. 3 receptor heterogeneity. Neuropharmacology 44:773-786, 2003.